Vaxart (NASDAQ:VXRT) stock jumped 37.9% premarket after the company reported positive early-stage data for its ...

Vaxart's (VXRT) shares soar 37% after positive early trial results for its oral norovirus vaccine. Read more here.

USA-based biotech Vaxart has reported positive top-line results from a Phase I trial comparing its second-generation oral ...

SOUTH SAN FRANCISCO, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its ...

SOUTH SAN FRANCISCO - Vaxart, Inc. (NASDAQ:VXRT), a clinical-stage biotechnology company with a market capitalization of approximately $90 million and shares down nearly 49% over the past year ...

Investing.com -- Vaxart Inc (NASDAQ: VXRT) stock surged 70% after the clinical-stage biotechnology company reported positive topline results from its Phase 1 trial evaluating second-generation ...

A California-based biotech company stole the show on Wednesday after the company reported positive clinical data ...

Vaxart, Inc. announced that it has obtained approval from the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) to begin dosing ...

Company Urges Stockholders to Vote FOR Reverse Stock Split Proposal by 11:59 p.m. Eastern Time on June 1, 2025 SOUTH SAN FRANCISCO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) ...

May 28, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” OR “Vaxart”) today answers additional frequently asked stockholder questions it has received from retail ...

Vaxart, Inc. announced the approval of equity awards for its new Chief Financial Officer, Jeroen Grasman, effective May 19, 2025, as an inducement for his joining the company. The awards include ...